Screener
Pelthos Therapeutics PTHS Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Pelthos Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Pelthos Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001919246-26-000070
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total other (expense) income | 2,850 | (134) |
| Net loss before provision for income taxes | (10,238) | (1,968) |
| Provision for income taxes | — | — |
| Net loss | $(10,238) | $(1,968) |
| Other comprehensive income: | ||
| Change in fair value of convertible debt due to instrument credit risk | 3,189 | — |
| Comprehensive loss | $(7,049) | $(1,968) |
| Net loss per common share - basic and diluted | $(3.09) | $(3.21) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Pelthos Therapeutics's net income?
- Pelthos Therapeutics (PTHS) reported net income of -$10.24M in Q1 2026.
- How has Pelthos Therapeutics's net income changed year-over-year?
- Pelthos Therapeutics's net income decreased by 420.2% year-over-year, from -$1.97M to -$10.24M.
- What is the long-term trend for Pelthos Therapeutics's net income?
- Over 3 years (2022 to 2025), Pelthos Therapeutics's net income has grown at a 160.2% compound annual growth rate (CAGR), from -$2.46M to -$43.32M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Pelthos Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude